Tumore dell’endometrio avanzato/ricorrente, con l’anti-PD-1 dostarlimab risposte rapide e durature

Important data for women diagnosed with endometrial cancer are emerging from the American Society of Clinical Oncology (ASCO) congress. New results from a highly significant study, the GARNET trial, were presented at the conference. This study evaluated immunotherapy with the anti-PD-1 drug dostarlimab in previously treated women with advanced/recurrent endometrial cancer. In this interview, Professor Nicoletta Colombo, an expert in gynecological cancers, Professor of Gynecology and Obstetrics at the University of Milan-Bicocca and Director of the Gynecological Oncology Program at the European Institute of Oncology (IEO) in Milan, discusses the results of this study and their implications.